Biointaxis is a genomic treatment and technology development company. The current lead program develops a gene therapy treatment for Friedreich ataxia, a rare, inherited, progressive neurodegenerative disease that typically affects teenagers and young adults. They reestablished the neurological functions in mice models of friedreich ataxia.